Abbott Laboratories · NYSE:ABT
Abbott Laboratories — a:care Congress (November 2021)
40 slides from Abbott Laboratories's conference presentation, November 2021
Slide 1: Educational purposes disclaimer
This presentation is offered for educational purposes only, intended to serve as continuing medical education for health care professionals. The content of the presentation represents the views and opinions of the original creators of such content and does not necessarily represent the views or opin
Slide 2: Improving access to self-management support for patients with chronic conditions: digital solutions
A:CARE CONGRESS Improving access to self-management support for patients with chronic conditions: digital solutions Prof. John Piette Dr. Bernard Vrijens Prof. Enrique de Madaria Professor of Health Behavior & Health Professor of Biostatistics & Associate Professor of Gastroenterology, Miguel Hernán
Slide 3: Improving Access To Self-management Support: Prof. John Piette
Improving Access To Self-management Support For Patients With Chronic Conditions: Digital Solutions Prof. John Piette Professor of Health Behavior & Health Education & Director of the Center for Managing Chronic Disease at Ann Arbor Michigan, US GLO2208858 | Nov-21 | 3
Slide 4: Digital solutions can be defined along three dimensions
A digital solutions can be defined along three dimensions Sociodemographic population served Mobile technologies and communication channels Program goals and functions Proprietary and confidential — do not distribute GLO2208858 | Nov-21 | 4
Slide 5: Mobile technologies for improving self-care support
Mobile technologies for improving self-care support Special devices Smartphones Automated calls Text messages (IVR) (SMS) GLO2208858 | Nov-21 | 5
Slide 6: Digital solutions can be defined along three dimensions
A digital solutions can be defined along three dimensions Sociodemographic population served Mobile technologies and communication channels Program goals and functions Proprietary and confidential — do not distribute GLO2208858 | Nov-21 | 6
Slide 7: Treatment Adherence
Treatment Adherence Proprietary and confidential — do not distribute GLO2208858 | Nov-21 | 7
Slide 8: Monitoring
Monitoring Proprietary and confidential — do not distribute GLO2208858 | Nov-21 | 8
Slide 9: Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome
Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome Chia-shi Wang1, Jonathan P. Troost2, Larry A. Greenbaum1, Tarak Srivastava3, Kimberly Reidy4, Keisha Gibson5, Howard Trachtman6, John D. Piette7, Christine B. Sethna8, Kevin Meyers9, Katherine M. Dell10, Cheryl L. Tran11, Suzanne
Slide 10: Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome
Text Messaging for Disease Monitoring in Childhood Nephrotic Syndrome Chia-shi Wang1, Jonathan P. Troost2, Larry A. Greenbaum1, Tarak Srivastava3, Kimberly Reidy4, Keisha Gibson5, Howard Trachtman6, John D. Piette7, Christine B. Sethna8, Kevin Meyers9, Katherine M. Dell10, Cheryl L. Tran11, Suzanne
Slide 11: Lifestyle behaviors
Lifestyle behaviors Proprietary and confidential — do not distribute GLO2208858 | Nov-21 | 11
Slide 12: Interventions for weight management using text messaging
Interventions for weight management using text messaging Review A systematic review and meta-analysis of interventions for weight management using text messaging G. Siopis,1 T. Chey2 & M. Allman-Farinelli1 Forest plot: mean weight change in body weight of intervention and control participants with t
Slide 13: Complex behavioral health challenges
Complex behavioral health challenges Proprietary and confidential — do not distribute GLO2208858 | Nov-21 | 13
Slide 14: Tailored integrative Internet intervention for depression
Tailored integrative Internet intervention for depression Research Article Effectiveness of a tailored, integrative Internet intervention (deprexis) for depression: Updated meta-analysis Conal Twomey1, Gary O’Reilly1, Oliver Bültmann2, Björn Meyer 2,3,a 1. School of Psychology, University College Du
Slide 15: Interactive Voice Response-Based Self-management for Chronic Back Pain
JAMA Internal Medicine | Original investigation Interactive Voice Response-Based Self-management for Chronic Back Pain THE COPES NONINFERIORITY RANDOMIZED TRIAL Alicia A. Heapy. PhD; Diana M. Higgins. PhD; Joseph L. Goulet. PhD, Kathryn M. LaChappeIIe, MPH; Mary A. Driscoll. PhD; Rebecca A Czlapinsk
Slide 16: Interactive Voice Response-Based Self-management for Chronic Back Pain
JAMA Internal Medicine | Original investigation Interactive Voice Response-Based Self-management for Chronic Back Pain NUMBER OF TREATMENT WEEKS BY CONDITION THE COPES NONINFERIORITY RANDOMIZED TRIAL Alicia A. Heapy. PhD; Diana M. Higgins. PhD; Joseph L. Goulet. PhD, Kathryn M. LaChappeIIe, MPH; Mar
Slide 17: Improving Access To Self-management Support: Dr. Bernard Vrijens
Improving Access To Self-management Support For Patients With Chronic Conditions: Digital Solutions Dr. Bernard Vrijens, PhD AARDEX Group Liège University Honorary Member, ESPACOMP, Belgium GLO2208858 | Nov-21 | 17
Slide 18: Medication Intake Behavior
Medication Intake Behavior ~12 hoursvinterdose interval YOU CAN’T MANAGE WHAT YOU DON’T MEASURE Measure Manage GLO2208858 | Nov-21 | 19
Slide 19: The Unfortunate 80% Rule!
The Unfortunate 80% Rule! EACH OF THESE 6 PATIENTS TOOK THE SAME PERCENTAGE (81%) OF PRESCRIBED DOSES, WHICH SOUNDS GOOD, BUT LOOK ONCE DAILY DOSING TWICE DAILY DOSING The variability in all these cases poses a significant risk to clinical success Vrijens B et al., Assessment of medication adherence
Slide 20: Variable adherence creates drug-specific issues of efficacy, safety & drug resistance
Variable adherence creates drug-specific issues of efficacy, safety & drug resistance What’s Occasional toxicity going on? Periodic loss of effectiveness & emergence of drug resistance Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unr
Slide 21: Medication Event Monitoring System (MEMS)
Medication Event Monitoring System (MEMS®) MEASURE MANAGE 1 million users 70 countries 35 35 years MEMS® Hardware Ecosystem MEMS® Adherence Software 800+ Publications GLO2208858 | Nov-21 | 22
Slide 22: The Scientific Evidence
The Scientific Evidence MEASURE MANAGE Accuracy of the measurement methods Smart package monitoring 1 97% Up to ↑20% ↑ 50% Drug levels and markers 70% Pill count 60% Rating by care professionals 50% & Data-driven adherence feedback is the most effective means to empower Self report, ePRO, electronic
Slide 23: Empower Patients and Providers
Empower Patients and Providers Self-management and patient engagement in care Facilitate communication between the patient and providers (e.g. shared decision making) Consistency in the message delivered based on individual measures (e.g. multidisciplinary team) Individualized care based on data (e.
Slide 24: Digitally-Enabled Integrated Person-Centred Care
Digitally-Enabled Integrated Person-Centred Care1 BENEFITS FOR ALL STAKEHOLDERS – TIME IS RIPE FOR A CHANGE! Patients Providers Payers Industry • Improves quality, • Better use of time • Decrease healthcare • Maximise value of safety, and allocation expenditures on the molecule to effectiveness of •
Slide 25: Lock-down: The Impact Of COVID-19 On Patient Adherence
IMPROVING ACCESS TO SELF -MANAGEMENT SUPPORT FOR PATIENTS WITH CHRONIC CONDITIONS: DIGITAL SOLUTIONS Lock-down: The Impact Of COVID-19 On Patient Adherence Prof. Enrique de Madaria Miguel Hernández University, Elche Alicante’s University General Hospital President of the Spanish Association of Gastr
Slide 26: Disclosures
Disclosures HONORARIA FROM TAKEDA PHARMACEUTICAL COMPANY, ABBOTT AND MYLAN. GLO2208858 | Nov-21 | 28
Slide 27: COVID-19 pandemic
COVID-19 pandemic SINCE DEC 2019 TO SEPT 2021 226,418,202 cases 4,660,390 deaths KEY FEATURES OF COVID-19 Direct person-to-person respiratory transmission1 Primary transmission via respiratory particles, hand contamination by secretions1 Early reports: mild 81%, Severe 14%, critical 5%, 2.3% mortali
Slide 28: COVID-19 And Patients With Non-communicable Chronic Diseases
COVID-19 And Patients With Non-communicable Chronic Diseases EFFECTS OF THE LOCK DOWN ON RISK FACTORS Probable increase in habits like caloric/ salty food intake, tobacco use, alcohol and cannabis use1 After an initial decrease, the number of smokers have risen2 Decrease in the effectivity of smokin
Slide 29: Comorbidity and COVID-19
Comorbidity and COVID-19 COVID-19 CASE SURVEILLANCE, USA Any comorbidity No comorbidity 70 60 50 45 Percentage 40 30 20 20 10 8 2 0 Hospitalization Death Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton KE. Coronavirus Disease 2019 Case Surveillance - United
Slide 30: COVID-19 And Patients Receiving Chronic Treatments
COVID-19 And Patients Receiving Chronic Treatments DECREASED MEDICAL ADHERENCE? Fear of patients with comorbidity to have severe disease/ to die Fear of visiting healthcare facilities, decreased availability for general practitioners, collapse of hospitals -> 40% decline in outpatients visits in USA
Slide 31: Impact of COVID-19 on NCD resources and services, WHO survey
Impact of COVID-19 on noncommunicable disease (NCD) resources and services, WHO survey 75% countries in 2020 with Most countries had Main reasons: considerable degree of disruption in essential • Decrease in inpatient volume due disruption of NCD services services for hypertension, to the cancellati
Slide 32: Likelihood of discontinuing drug during COVID-19
Retrospective analysis on a dataset of 9.4 billion US prescription drug claims from 252 million patients from May 2019 through August 2020 LIKELIHOOD OF DISCONTINUING DRUG 3 2.8 Change in likelihood (%) 2 1.5 1 0.6 0.6 0 -0.2 -0.6 < adherence -1 > adherence N-E-Estradiol Dexmethylphenidate HCL Escit
Slide 33: COVID-19, medical adherence and low- and middle-income countries
COVID-19, medical adherence and low-and middle-income countries (LMICS) High disease burden: chronic infectious and non- communicable diseases1 • HIV/AIDS, tuberculosis, hepatitis, diabetes, cardiovascular diseases, cancers, chronic pulmonary diseases and mental illnesses2 LMICs often rely heavily o
Slide 34: ENABLE study: availability of forms of teleconsultation
European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE) cross-sectional study AVAILABILITY OF VARIOUS FORMS OF TELECONSULTATION 100 Higher GDP per capita: wider range of 100 teleconsultation 80 72 60 56 Percentage 38 40 20 20 12 0 E-mail Chat Phone Videoconsultation
Slide 35: ENABLE study: options for requesting chronic medication prescriptions
European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE) cross-sectional study AVAILABILITY OF OPTIONS FOR REQUESTING CHRONIC MEDICATION PRESCRIPTIONS 100 Higher GDP per capita: wider range of 86 teleconsultation 80 69 60 Percentage 49 49 40 35 32 21 20 0 E-mail Chat
Slide 36: Example: Pancreatic Enzyme Replacement Therapy (PERT)
Example: Pancreatic Enzyme Replacement Therapy (PERT) Pancreatic juice is needed for adequate digestion of food, particularly fats Many pancreas diseases/ conditions associated to Pancreatic Exocrine Insufficiency • Chronic pancreatitis • Acute pancreatitis • Pancreatic cancer • Cystic fibrosis • Pa
Slide 37: PERTCOVID survey
PERTCOVID survey Patients with PEI receiving PERT Impact of COVID-19 on adherence Gastroenterology Department, Alicante´s Univ. Gen. Hospital & Psychology Department, Miguel Hernandez University, Alicante, Spain Phases of development • June 2021: initial interviews of psychologist team with a small
Slide 38: PERTCOVID Survey results
PERTCOVID Survey 50 PATIENTS UNDER PERT, 92% CHRONIC PANCREATITIS, 4% ACUTE PANCREATITIS, 2% PANCREATIC CANCER, 2% PANCREATIC SURGERY 0: Never, 1: Seldom, 3: Sometimes, 4: Often, 5: Always Before COVID-19 During lockdown After lockdown 5 p=0.8 p=0.001 p=0.004 p=0.001 p=0.8 4 3 Ordinal scale 2,36 2,1
Slide 39: PERTCOVID Survey results
PERTCOVID Survey 50 PATIENTS UNDER PERT, 92% CHRONIC PANCREATITIS, 4% ACUTE PANCREATITIS, 2% PANCREATIC CANCER, 2% PANCREATIC SURGERY 0: no association, 10: absolute association p=0.8 Before COVID-19 During lockdown After lockdown 10 8,26 8,26 8,28 8 Ordinal scale 6 4 2 0 Perception of association b
Slide 40: Conclusions
CONCLUSIONS The pandemic seems to be associated with increase in unhealthy habits Risk factors for decreased medical adherence: fear of visiting healthcare facilities + decreased availability, decreased awareness about the importance of chronic diseases, economic crisis, disruption of drug supply ch
Abbott Laboratories — a:care Congress (November 2021) on 6ix